564 related articles for article (PubMed ID: 26466021)
1. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.
Urban P; Meredith IT; Abizaid A; Pocock SJ; Carrié D; Naber C; Lipiecki J; Richardt G; Iñiguez A; Brunel P; Valdes-Chavarri M; Garot P; Talwar S; Berland J; Abdellaoui M; Eberli F; Oldroyd K; Zambahari R; Gregson J; Greene S; Stoll HP; Morice MC;
N Engl J Med; 2015 Nov; 373(21):2038-47. PubMed ID: 26466021
[TBL] [Abstract][Full Text] [Related]
2. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk.
Windecker S; Latib A; Kedhi E; Kirtane AJ; Kandzari DE; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Hudec M; Poliacikova P; Abdul Ghapar AKB; Selvaraj K; Petrov I; Mylotte D; Pinar E; Moreno R; Fabbiocchi F; Pasupati S; Kim HS; Aminian A; Tie C; Wlodarczak A; Hur SH; Marx SO; Jankovic I; Brar S; Bousquette L; Liu M; Stone GW;
N Engl J Med; 2020 Mar; 382(13):1208-1218. PubMed ID: 32050061
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Polymer-Free Biolimus A9-Coated Versus Bare-Metal Stents in Orally Anticoagulated Patients: 2-Year Results of the LEADERS FREE Oral Anticoagulation Substudy.
Carrié D; Menown I; Oldroyd K; Copt S; Talwar S; Maillard L; Morice MC; Teik LS; Lang I; Urban P
JACC Cardiovasc Interv; 2017 Aug; 10(16):1633-1642. PubMed ID: 28838473
[TBL] [Abstract][Full Text] [Related]
4. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
5. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.
Garot P; Morice MC; Tresukosol D; Pocock SJ; Meredith IT; Abizaid A; Carrié D; Naber C; Iñiguez A; Talwar S; Menown IBA; Christiansen EH; Gregson J; Copt S; Hovasse T; Lurz P; Maillard L; Krackhardt F; Ong P; Byrne J; Redwood S; Windhövel U; Greene S; Stoll HP; Urban P;
J Am Coll Cardiol; 2017 Jan; 69(2):162-171. PubMed ID: 27806919
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy.
Urban P; Abizaid A; Chevalier B; Greene S; Meredith I; Morice MC; Pocock S
Am Heart J; 2013 May; 165(5):704-9. PubMed ID: 23622906
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.
Kaiser C; Galatius S; Jeger R; Gilgen N; Skov Jensen J; Naber C; Alber H; Wanitschek M; Eberli F; Kurz DJ; Pedrazzini G; Moccetti T; Rickli H; Weilenmann D; Vuillomenet A; Steiner M; Von Felten S; Vogt DR; Wadt Hansen K; Rickenbacher P; Conen D; Müller C; Buser P; Hoffmann A; Pfisterer M;
Circulation; 2015 Jan; 131(1):74-81. PubMed ID: 25411159
[TBL] [Abstract][Full Text] [Related]
8. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
9. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
Christiansen EH; Jensen LO; Thayssen P; Tilsted HH; Krusell LR; Hansen KN; Kaltoft A; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Villadsen AB; Ravkilde J; Aarøe J; Madsen M; Thuesen L; Lassen JF;
Lancet; 2013 Feb; 381(9867):661-9. PubMed ID: 23374649
[TBL] [Abstract][Full Text] [Related]
10. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial.
Räber L; Kelbæk H; Ostojic M; Baumbach A; Heg D; Tüller D; von Birgelen C; Roffi M; Moschovitis A; Khattab AA; Wenaweser P; Bonvini R; Pedrazzini G; Kornowski R; Weber K; Trelle S; Lüscher TF; Taniwaki M; Matter CM; Meier B; Jüni P; Windecker S;
JAMA; 2012 Aug; 308(8):777-87. PubMed ID: 22910755
[TBL] [Abstract][Full Text] [Related]
11. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
Klauss V; Serruys PW; Pilgrim T; Buszman P; Linke A; Ischinger T; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; van Geuns RJ; van Es GA; Kalesan B; Wenaweser P; Jüni P; Windecker S
JACC Cardiovasc Interv; 2011 Aug; 4(8):887-95. PubMed ID: 21851904
[TBL] [Abstract][Full Text] [Related]
12. Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial.
Mehran R; Chandrasekhar J; Urban P; Lang IM; Windhoevel U; Spaulding C; Copt S; Stoll HP; Morice MC;
JAMA Cardiol; 2020 Aug; 5(8):939-947. PubMed ID: 32432718
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
Stone GW; Lansky AJ; Pocock SJ; Gersh BJ; Dangas G; Wong SC; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Möckel M; Ochala A; Kellock A; Parise H; Mehran R;
N Engl J Med; 2009 May; 360(19):1946-59. PubMed ID: 19420364
[TBL] [Abstract][Full Text] [Related]
14. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
15. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Smits PC; Hofma S; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; Vuillomenet A; Serra A; Nouche RT; den Heijer P; van der Ent M
Lancet; 2013 Feb; 381(9867):651-60. PubMed ID: 23374650
[TBL] [Abstract][Full Text] [Related]
16. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
[TBL] [Abstract][Full Text] [Related]
17. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
18. Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial.
Jensen Lisette Okkels; Maeng M; Raungaard B; Kahlert J; Ellert J; Jakobsen L; Villadsen AB; Veien KT; Kristensen SD; Ahlehoff O; Carstensen S; Christensen MK; Terkelsen CJ; Engstroem T; Hansen KN; Bøtker HE; Aaroe J; Thim T; Thuesen L; Freeman P; Aziz A; Eftekhari A; Junker A; Jensen SE; Lassen JF; Hansen HS; Christiansen EH;
Circulation; 2020 Jun; 141(25):2052-2063. PubMed ID: 32434381
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: Rationale and design of the randomized SORT OUT IX trial.
Jensen LO; Maeng M; Raungaard B; Engstrøm T; Hansen HS; Jensen SE; Bøtker HE; Kahlert J; Lassen JF; Christiansen EH
Am Heart J; 2019 Jul; 213():1-7. PubMed ID: 31055192
[TBL] [Abstract][Full Text] [Related]
20. Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry.
Urban P; Valdés M; Menown I; Eberli F; Alhaddad I; Hildick-Smith D; Iosseliani D; Roffi M; Oldroyd K; Kalloudi E; Eerdmans P; Berland J; Kleber FX;
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1151-60. PubMed ID: 25683225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
